Therapy for minimal residual tumour disease: beta-galactosylceramide inhibits growth of recurrent HPV16-associated neoplasms after surgery and chemotherapy

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F68378050%3A_____%2F10%3A00333598" target="_blank" >RIV/68378050:_____/10:00333598 - isvavai.cz</a>

Výsledek na webu

—

DOI - Digital Object Identifier

—

Jazyk výsledku

angličtina

Název v původním jazyce

Therapy for minimal residual tumour disease: beta-galactosylceramide inhibits growth of recurrent HPV16-associated neoplasms after surgery and chemotherapy

Popis výsledku v původním jazyce

This study was focused on tumour-inhibitory effects of 12 carbon acyl chain beta-galactosylceramide (C12 beta-D-GalactosylCeramide) on the growth of HPV16-associated neoplasms transplanted in syngeneic mice. Treatment of tumour-bearing mice with beta-galactosylceramide 3-14 days after tumour cell transplantation significantly inhibited growth of the MHC class I-positive (TC-1), as well as MHC class I-deficient (TC-1/A9) HPV16-asssociated tumours. Administration of beta-galactosylceramide after surgicalremoval of TC-1 tumours inhibited growth of tumour recurrences. Similar results were obtained in the treatment of the tumours after chemotherapy. Beta-galactosylceramide treatment turned out to be also synergistic with immunotherapy based on administration of IL-12-producing cellular vaccines. These results suggest that beta-galactosylceramide can be effective for treatment of minimal residual tumour disease as well as an adjuvant for cancer immunotherapy.

Název v anglickém jazyce

Therapy for minimal residual tumour disease: beta-galactosylceramide inhibits growth of recurrent HPV16-associated neoplasms after surgery and chemotherapy

Popis výsledku anglicky

This study was focused on tumour-inhibitory effects of 12 carbon acyl chain beta-galactosylceramide (C12 beta-D-GalactosylCeramide) on the growth of HPV16-associated neoplasms transplanted in syngeneic mice. Treatment of tumour-bearing mice with beta-galactosylceramide 3-14 days after tumour cell transplantation significantly inhibited growth of the MHC class I-positive (TC-1), as well as MHC class I-deficient (TC-1/A9) HPV16-asssociated tumours. Administration of beta-galactosylceramide after surgicalremoval of TC-1 tumours inhibited growth of tumour recurrences. Similar results were obtained in the treatment of the tumours after chemotherapy. Beta-galactosylceramide treatment turned out to be also synergistic with immunotherapy based on administration of IL-12-producing cellular vaccines. These results suggest that beta-galactosylceramide can be effective for treatment of minimal residual tumour disease as well as an adjuvant for cancer immunotherapy.

Druh

J_x - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)

CEP obor

EB - Genetika a molekulární biologie

OECD FORD obor

—

Projekt

Výsledek vznikl pri realizaci vícero projektů. Více informací v záložce Projekty.

Návaznosti

P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)<br>Z - Vyzkumny zamer (s odkazem do CEZ)

Rok uplatnění

2010

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

International Journal of Cancer

ISSN

0020-7136

e-ISSN

—

Svazek periodika

126

Číslo periodika v rámci svazku

12

Stát vydavatele periodika

DE - Spolková republika Německo

Počet stran výsledku

2

Strana od-do

—

Kód UT WoS článku

000277551100025

EID výsledku v databázi Scopus

—